KUALA LUMPUR, July 29 (Bernama) -- Bursa Malaysia rebounded to close higher on Wednesday on selective buying of defensive stocks after a volatile trading session. IPPFA Sdn Bhd director of investment strategy and country economist Mohd Sedek Jantan said consumer products and services stocks lifted the key index higher, overcoming lingering geopolitical concerns. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 3.08 points to 1,715.56 from yesterday’s close of 1,712.48. The benchmark index, which opened 1.91 points higher at 1,714.39, moved between 1,710.79 and 1,720.59 during the day’s trading. In the broader market, gainers outstripped decliners 550 to 476, while 612 counters were unchanged, 1,129 untraded, and 48 suspended. Turnover rose to 2.96 billion units valued at RM2.48 billion from 2.94 billion units valued at RM2.56 billion on Tuesday.
Why Analysts Like Pfizer:
Pfizer is profitable and undervalued, offering solid income through dividends and room for price growth.
The stock recently broke out of a bullish price pattern, showing momentum for further gains.
Technical indicators suggest an uptrend is in place, with the short-term average price staying above the longer-term average.
Financial Outlook:
Pfizer’s expected performance over the next 3 years:
| Year | Revenue | Net Profit |
|---|---|---|
| 2025 | ~$62.5 billion | ~$17.2 billion |
| 2026 | ~$62.4 billion | ~$17.8 billion |
| 2027 | ~$61.2 billion | ~$17.8 billion |
Net profit margin expected to stay strong at around 28.4%.
Net profit growth over the next 3 years is forecasted at over 30%.
What the Charts Are Saying:
Pfizer’s price recently broke above a short-term resistance level.
Strong buying momentum is confirmed by consistent higher lows and a bullish candlestick pattern (white Marubozu).
Near-term price targets:
Resistance: $25.98 and $27.00
Support: $24.37 and $23.79
Things to Keep in Mind:
The pharmaceutical sector is defensive, which makes Pfizer a steady long-term choice.
Risks include regulatory pressures, currency fluctuations, and pipeline execution.
Despite near-term volatility, the company’s profit margins and dividends offer stability.
Final Take:
With a solid dividend, strong earnings outlook, and signs of price recovery, Pfizer is a compelling option for income-focused and long-term investors. Analysts recommend buying now, with the stock offering a combination of growth, yield, and resilience.
Comments
Post a Comment